October 19, 2011
Exposure-response analysis of eslicarbazepine acetate as adjunctive treatment of patients with partial-onset seizures
October 18, 2011
It’s not gloom and doom if it helps to frame the problem.
In a recent article, Peter Thiel does an excellent job of linking the need for advancements in technology and science with broader societal crises.
October 17, 2011
Virtual Physiological Human
Cognigen was invited to use its expertise in modeling and simulation to comment on a recently published policy brief called: Policy needs and options for a common approach towards modelling and simulation of human physiology and diseases with a focus on the Virtual Physiological Human.
October 12, 2011
Register for NONMEM Course
Registration is now available for 3 courses to be offered by the University at Buffalo School of Pharmacy and Pharmaceutical Sciences in May 2012.
October 12, 2011
Drug Development Boot Camp
Cognigen CEO Ted Grasela will lecture on pharmacokinetics at the Drug Development Boot Camp: An Intensive Two Day Course for Biotech and Pharma Company Executives.
October 7, 2011
Ted at PoC Conference
Ted Grasela, President and CEO of Cognigen Corporation, presented Pharmacometrics and PoC: Preventative Care for Drug Development on October 4, 2011, at the 3rd Annual Accelerating Proof-of-Concept Conference.
October 7, 2011
Poster at EASD in Lisbon
A poster titled Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling of Subcutaneous (SC) LY2189102, a Neutralizing IL-1 beta Antibody, in Patients with Type 2 Diabetes Mellitus was presented at the European Association for the Study of Diabetes in September 2011. Cognigen scientist Sebastien Bihorel was the primary analyst on this effort.
October 6, 2011
Pharmacokinetic (PK) and pharmacodynamic (PD) modeling of subcutaneous (SC) LY2189102, a neutralizing IL-1 beta antibody, in patients with type 2 diabetes mellitus
September 16, 2011
Cognigen Posters at ACoP
Two posters describing Cognigen analyses were presented at the 2011 American Conference on Pharmacometrics (ACoP) in April.
September 16, 2011
PAGE Meeting in Athens
A poster titled Semi-mechanistic PK/PD Model of the Effect of Odanacatib, a Cathepsin K Inhibitor, on Bone Turnover to Characterize Lumbar Spine and Distal Forearm Bone Mineral Density in A Phase IIb Study of Postmenopausal Women was presented at the 20th annual meeting of the Population Approach Group in Europe (PAGE). Cognigen scientist David Jaworowicz was the primary analyst on this effort.
